isoniazid and azomycin

isoniazid has been researched along with azomycin in 27 studies

Research

Studies (27)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (14.81)29.6817
2010's20 (74.07)24.3611
2020's3 (11.11)2.80

Authors

AuthorsStudies
Almeida, D; Bishai, WR; Grosset, JH; Nuermberger, E; Peloquin, CA; Rosenthal, I; Tyagi, S; Williams, KN1
Aly, S; Andries, K; Basaraba, RJ; Cantarero, L; Ehlers, S; Hoff, D; Lenaerts, AJ; Orme, IM1
Zhang, Y1
Grosset, J; Nuermberger, E; Tasneen, R; Tyagi, S; Williams, K1
Cole, ST; Dhar, N; Ha, YH; Hartkoorn, RC; Sala, C; Schneider, P; Zhang, M1
Becker, P; Dawson, R; Diacon, AH; Donald, PR; du Bois, J; Erondu, N; Ginsberg, AM; Narunsky, K; Spigelman, MK; van Niekerk, C; Venter, A1
Amoabeng, O; Andries, K; Mdluli, KE; Minkowski, A; Nuermberger, EL; Peloquin, CA; Taylor, D; Wallis, RS; Williams, K1
Cole, ST; Hartkoorn, RC; Lechartier, B1
Arena, A; Arrieta, F; Bloomer, WD; Papadopoulou, MV; Rebolledo, JC; Rosenzweig, HS; Smith, DK1
Dutta, NK; Karakousis, PC1
Burger, DA; Conradie, A; Dawson, R; Diacon, AH; Donald, PR; Eisenach, K; Everitt, D; Ive, P; Mendel, CM; Ntinginya, NE; Page-Shipp, L; Pym, A; Reither, K; Schall, R; Spigelman, M; van Niekerk, C; Variava, E; Venter, A; von Groote-Bidlingmaier, F1
Bhatnagar, R; Bhuyan, S; Das, B; Garhyan, J; Kalita, D; Pulu, I1
Geiter, L; Mallikaarjun, S; Paccaly, A; Patil, S; Petersen, C; Shoaf, SE; Wells, C1
Centis, R; D'Ambrosio, L; Fuentes, Z; Migliori, GB; Sotgiu, G; Tiberi, S; Zumla, A1
Mendel, C; Murray, S; Spigelman, M1
Akkerman, OW; Alffenaar, JW; Bolhuis, MS; de Lange, WCM; de Vries, G; de Zwaan, R; Dedicoat, M; Frijlink, HW; Gajraj, R; Grasmeijer, F; Hagedoorn, P; Kerstjens, HAM; Smith, G; van der Werf, TS; van Soolingen, D1
Fujiwara, M; Hariguchi, N; Kawasaki, M; Liu, Y; Matsumoto, M1
Kremer, L; Kumar, V; Viljoen, A1
Falzon, D; Halleux, CM; Jaramillo, E; Merle, C; Mirzayev, F; Olliaro, P; Weyer, K1
Flexner, C; Moss, DM; Owen, A; Podany, AT; Rajoli, RKR; Siccardi, M; Swindells, S1
Balanag, V; Bielskiene, V; Cadena, E; Caoili, J; Cirule, A; Danilovits, M; Davidaviciene, E; Domente, L; Geiter, LJ; Gupta, R; Hafkin, J; Hittel, N; Lizarbe, V; Patientia, R; Petersen, C; Sanchez, E; Segura, P; Staples, S; Ticona, E; Variava, E; von Groote-Bidlingmaier, F; Wells, C; Yu, C1
Okumura, M; Yoshiyama, T1
Nair, SG; Patel, DB; Patel, HD; Rathwa, SK; Vasava, MS1
Fattorini, L; Giannoni, F; Iacobino, A; Pardini, M; Piccaro, G1
Kumari, D; Perveen, S; Sharma, R; Singh, K1
Carr, W; Converse, PJ; Dartois, V; Dooley, KE; Garcia, A; Kurbatova, E; Nuermberger, EL; Stout, JE; Tasneen, R; Vernon, AA; Zimmerman, MD1
Barnes, G; Dawson, R; Dooley, KE; Dorman, SE; Friedman, A; Gupte, N; Hendricks, B; Ignatius, EH; Narunsky, K; Smit, T; Whitelaw, C1

Reviews

3 review(s) available for isoniazid and azomycin

ArticleYear
Advances in the treatment of tuberculosis.
    Clinical pharmacology and therapeutics, 2007, Volume: 82, Issue:5

    Topics: Adamantane; AIDS-Related Opportunistic Infections; Animals; Anti-Bacterial Agents; Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Drugs, Investigational; Ethylenediamines; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; Isoniazid; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Rifampin; Treatment Refusal; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary

2007
Development of new drug-regimens against multidrug-resistant tuberculosis.
    The Indian journal of tuberculosis, 2019, Volume: 66, Issue:1

    Topics: Adamantane; Antitubercular Agents; Diarylquinolines; Drug Development; Drug Therapy, Combination; Duration of Therapy; Ethambutol; Ethylenediamines; Humans; Isoniazid; Macrolides; Medication Adherence; Nitroimidazoles; Oxazolidinones; Pyrazinamide; Rifampin; Tuberculosis, Multidrug-Resistant

2019
Tuberculosis drug discovery: Progression and future interventions in the wake of emerging resistance.
    European journal of medicinal chemistry, 2022, Feb-05, Volume: 229

    Topics: Antitubercular Agents; Diarylquinolines; Drug Therapy, Combination; Ethambutol; Extensively Drug-Resistant Tuberculosis; Humans; Isoniazid; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Rifampin

2022

Trials

5 trial(s) available for isoniazid and azomycin

ArticleYear
Phase II dose-ranging trial of the early bactericidal activity of PA-824.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:6

    Topics: Adolescent; Adult; Antitubercular Agents; Drug Administration Schedule; Ethambutol; Female; Humans; Isoniazid; Male; Middle Aged; Nitroimidazoles; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary; Young Adult

2012
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pul
    Lancet (London, England), 2015, May-02, Volume: 385, Issue:9979

    Topics: Adolescent; Adult; Antitubercular Agents; Colony Count, Microbial; Drug Therapy, Combination; Ethambutol; Female; Fluoroquinolones; Humans; Isoniazid; Male; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Rifampin; South Africa; Sputum; Tanzania; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult

2015
Delamanid Coadministered with Antiretroviral Drugs or Antituberculosis Drugs Shows No Clinically Relevant Drug-Drug Interactions in Healthy Subjects.
    Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:10

    Topics: Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Drug Combinations; Drug Interactions; Ethambutol; Female; Healthy Volunteers; Humans; Isoniazid; Male; Nitroimidazoles; Oxazoles; Pyrazinamide; Rifampin

2016
Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial.
    The Lancet. Respiratory medicine, 2019, Volume: 7, Issue:3

    Topics: Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Isoniazid; Male; Middle Aged; Nitroimidazoles; Oxazoles; Rifampin; Sputum; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary

2019
Assessing Pretomanid for Tuberculosis (APT), a Randomized Phase 2 Trial of Pretomanid-Containing Regimens for Drug-Sensitive Tuberculosis: 12-Week Results.
    American journal of respiratory and critical care medicine, 2023, 04-01, Volume: 207, Issue:7

    Topics: Animals; Antitubercular Agents; Drug Therapy, Combination; Isoniazid; Mice; Nitroimidazoles; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary

2023

Other Studies

19 other study(ies) available for isoniazid and azomycin

ArticleYear
Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis.
    Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:8

    Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Disease Models, Animal; Drug Therapy, Combination; Ethambutol; Female; Isoniazid; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Rifampin; Secondary Prevention; Time Factors; Tuberculosis, Pulmonary

2006
Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:9

    Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Diarylquinolines; Female; Granuloma; Guinea Pigs; Hypoxia; Isoniazid; Lung; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Quinolines; Radiation-Sensitizing Agents; Rifampin; Spleen; Tuberculosis

2007
Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis.
    Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:10

    Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Isoniazid; Lung; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Nitroimidazoles; Pyrazinamide; Recurrence; Rifampin; Tuberculosis, Pulmonary

2008
Simple model for testing drugs against nonreplicating Mycobacterium tuberculosis.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:10

    Topics: Antitubercular Agents; Aza Compounds; Fluoroquinolones; Isoniazid; Meropenem; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Quinolines; Rifampin; Streptomycin; Thienamycins

2010
Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:6

    Topics: Animals; Antitubercular Agents; Drug Therapy, Combination; Female; Isoniazid; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Nitroimidazoles; Oxazolidinones; Pyrazinamide; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant

2012
In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:11

    Topics: Adamantane; Antitubercular Agents; Aza Compounds; Diarylquinolines; Drug Combinations; Drug Synergism; Ethambutol; Ethylenediamines; Fluoroquinolones; Isoniazid; Meropenem; Microbial Sensitivity Tests; Microbial Viability; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Quinolines; Rifampin; Spiro Compounds; Thiazines; Thienamycins

2012
Nitrotriazole- and imidazole-based amides and sulfonamides as antitubercular agents.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:11

    Topics: Amides; Animals; Antitubercular Agents; Cell Line; Drug Evaluation, Preclinical; Drug Resistance, Bacterial; Imidazoles; Isoniazid; Macrophages; Mice; Microbial Sensitivity Tests; Microbial Viability; Mycobacterium tuberculosis; Nitroimidazoles; Sulfonamides; Tuberculosis, Pulmonary

2014
PA-824 is as effective as isoniazid against latent tuberculosis infection in C3HeB/FeJ mice.
    International journal of antimicrobial agents, 2014, Volume: 44, Issue:6

    Topics: Animals; Antitubercular Agents; Disease Models, Animal; Female; Isoniazid; Latent Tuberculosis; Lung; Mice; Mice, Inbred C3H; Mycobacterium tuberculosis; Nitroimidazoles; Rifampin

2014
Preclinical and Clinical Evidence of Mycobacterium tuberculosis Persistence in the Hypoxic Niche of Bone Marrow Mesenchymal Stem Cells after Therapy.
    The American journal of pathology, 2015, Volume: 185, Issue:7

    Topics: Adapalene; Animals; Antitubercular Agents; Bone Marrow Cells; Cell Hypoxia; Down-Regulation; Female; Green Fluorescent Proteins; Humans; Isoniazid; Lung; Mesenchymal Stem Cells; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Nitroimidazoles; Radiation-Sensitizing Agents; Specific Pathogen-Free Organisms; Tuberculosis, Pulmonary; Up-Regulation

2015
Applicability of the shorter 'Bangladesh regimen' in high multidrug-resistant tuberculosis settings.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2017, Volume: 56

    Topics: Antitubercular Agents; Clinical Protocols; Diarylquinolines; Drug Therapy, Combination; Ethambutol; Fluoroquinolones; Humans; Isoniazid; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Tuberculosis, Multidrug-Resistant; World Health Organization

2017
TB Alliance regimen development for multidrug-resistant tuberculosis.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2016, 12-01, Volume: 20, Issue:12

    Topics: Antitubercular Agents; Clinical Protocols; Diarylquinolines; Dose-Response Relationship, Drug; Ethambutol; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; Isoniazid; Linezolid; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Randomized Controlled Trials as Topic; Research Design; Rifampin; Tuberculosis, Multidrug-Resistant

2016
Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis.
    The European respiratory journal, 2018, Volume: 51, Issue:3

    Topics: Adult; Antitubercular Agents; Colistin; Diarylquinolines; Drug Synergism; Extensively Drug-Resistant Tuberculosis; Humans; Isoniazid; Male; Medication Adherence; Mycobacterium tuberculosis; Netherlands; Nitroimidazoles; Oxazoles; Patient Isolation; Phenotype; Trimethoprim, Sulfamethoxazole Drug Combination; United Kingdom

2018
Mechanisms of resistance to delamanid, a drug for Mycobacterium tuberculosis.
    Tuberculosis (Edinburgh, Scotland), 2018, Volume: 108

    Topics: Antitubercular Agents; Bacterial Proteins; Chromatography, High Pressure Liquid; DNA Mutational Analysis; Drug Resistance, Multiple, Bacterial; Genotype; Isoniazid; Microbial Sensitivity Tests; Mutation; Mycobacterium bovis; Mycobacterium tuberculosis; Nitroimidazoles; Nitroreductases; Oxazoles; Phenotype; Riboflavin

2018
Alkylated/aminated nitroimidazoles and nitroimidazole-7-chloroquinoline conjugates: Synthesis and anti-mycobacterial evaluation.
    Bioorganic & medicinal chemistry letters, 2018, 05-01, Volume: 28, Issue:8

    Topics: Animals; Antitubercular Agents; Cell Line; Isoniazid; Mice; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Nitroimidazoles; Quinolines; Structure-Activity Relationship

2018
The World Health Organization global aDSM database: generating evidence on the safety of new treatment regimens for drug-resistant tuberculosis.
    The European respiratory journal, 2018, Volume: 51, Issue:3

    Topics: Antitubercular Agents; Communicable Disease Control; Databases, Factual; Diarylquinolines; Humans; Infectious Disease Medicine; Isoniazid; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Patient Safety; Public Health; Rifampin; Tuberculosis, Multidrug-Resistant; World Health Organization

2018
Modelling the long-acting administration of anti-tuberculosis agents using PBPK: a proof of concept study.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2018, 08-01, Volume: 22, Issue:8

    Topics: Adolescent; Adult; Antitubercular Agents; Diarylquinolines; Drug Administration Schedule; Drug Liberation; Drug Therapy, Combination; Female; Humans; Injections, Intramuscular; Isoniazid; Latent Tuberculosis; Male; Middle Aged; Nitroimidazoles; Oxazoles; Proof of Concept Study; Rifampin; Treatment Outcome; Young Adult

2018
[EXPERIENCE OF USE OF NEW ANTI-TUBERCULOUS DRUG, DELAMANID IN MULTI- AND EXTENSIVELY DRUG RESISTANT TUBERCULOSIS CASES IN OUR HOSPITAL].
    Kekkaku : [Tuberculosis], 2016, Volume: 91, Issue:11-12

    Topics: Adult; Antitubercular Agents; Extensively Drug-Resistant Tuberculosis; Female; Humans; Isoniazid; Male; Middle Aged; Nitroimidazoles; Oxazoles

2016
The Combination Rifampin-Nitazoxanide, but Not Rifampin-Isoniazid-Pyrazinamide-Ethambutol, Kills Dormant Mycobacterium tuberculosis in Hypoxia at Neutral pH.
    Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:7

    Topics: Antitubercular Agents; Drug Combinations; Drug Therapy, Combination; Ethambutol; Humans; Hydrogen-Ion Concentration; Hypoxia; Isoniazid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazolidinones; Pyrazinamide; Rifampin; Tuberculosis

2019
Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models.
    Antimicrobial agents and chemotherapy, 2022, 04-19, Volume: 66, Issue:4

    Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Diarylquinolines; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combination; Isoniazid; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Rifabutin; Tuberculosis

2022